We are live on ! Find out more
AKRO

Akero Therapeutics
AKRO

Delisted

AKRO was delisted on the 8th of December, 2025.

Back to rankings

48 hedge funds and large institutions have $205M invested in Akero Therapeutics in 2019 Q2 according to their latest regulatory filings, with 48 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

39.46% more ownership

Funds ownership: 0% → 39.46% (+39%)

Holders
48
Holders Change
+48
Holders Change %
–
% of All Funds
1.04%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
48
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VP
venBio Partners
California
+$75M
2
RG
Redmile Group
California
+$22.2M
3
CAM
Cormorant Asset Management
Massachusetts
+$14.6M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$14.4M
5
BI
BVF Inc
California
+$12.3M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
LCM
26
Landscape Capital Management
New Jersey
$485K +$481K +25,352 New
ZP
27
Zimmer Partners
New York
$479K +$474K +25,000 New
LCM
28
Laurion Capital Management
New York
$431K +$426K +22,500 New
CS
29
Candriam SCA
Luxembourg
$381K +$379K +20,000 New
BCM
30
BlueCrest Capital Management
Jersey
$326K +$322K +17,000 New
DKCM
31
Davidson Kempner Capital Management
New York
$294K +$284K +15,000 New
Norges Bank
32
Norges Bank
Norway
$287K +$284K +15,000 New
Northern Trust
33
Northern Trust
Illinois
$217K +$215K +11,328 New
MCM
34
Moore Capital Management
New York
$192K +$190K +10,000 New
SG Americas Securities
35
SG Americas Securities
New York
$192K +$190K +10,000 New
CSS
36
Cubist Systematic Strategies
Connecticut
$87K +$86.4K +4,560 New
PHK
37
Point72 Hong Kong
Hong Kong
$77K +$76K +4,008 New
TAM
38
Tiverton Asset Management
Delaware
$54K +$53.1K +2,800 New
Victory Capital Management
39
Victory Capital Management
Texas
$31K +$30.5K +1,608 New
TRCT
40
Tower Research Capital (TRC)
New York
$26K +$26.2K +1,381 New
GAM
41
Griffin Asset Management
New York
$25K +$24.6K +1,300 New
UBS Group
42
UBS Group
Switzerland
$21K +$21.2K +1,118 New
GHCM
43
Glen Harbor Capital Management
California
$14K +$14.2K +748 New
MCIM
44
Meadow Creek Investment Management
Georgia
$12K +$11.7K +616 New
EP
45
Elkfork Partners
Oregon
$9K +$9.17K +484 New
CCA
46
Catalyst Capital Advisors
New York
$8K +$7.88K +416 New
TAM
47
Tyers Asset Management
Texas
$7K +$6.67K +352 New
Morgan Stanley
48
Morgan Stanley
New York
$2K +$1.9K +100 New
1
2

AKRO Hedge Fund Activity: Q2 2019 in Review

48 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q2 2019, worth a combined $205M.

Buyers outnumbered sellers: 48 funds opened new AKRO positions and 0 closed out — a net gain of 48 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was venBio Partners, opening a new position worth an estimated $75M.

  • 48 institutional investors held Akero Therapeutics (AKRO) as of Q2 2019, up from 0 in Q1 2019.
  • Funds reported $205M of Akero Therapeutics stock for Q2 2019.
  • 48 funds opened new Akero Therapeutics positions in Q2 2019 and 0 closed out, a net change of +48 holders.
  • The largest Akero Therapeutics buyer in Q2 2019 was venBio Partners, an estimated $75M added.

Based on aggregated 13F filings for Q2 2019.